Overview |
bs-9845R-RBITC |
GDN Polyclonal Antibody, RBITC Conjugated |
WB, IF(IHC-P) |
Human, Mouse, Rat |
Specifications |
RBITC |
Rabbit |
KLH conjugated synthetic peptide derived from human GDN/SERPINE2 |
301-398/398 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
5270 |
P07093 |
Secreted, Extracellular domain |
Glia derived nexin; Protease inhibitor 7; GDN; GDN_HUMAN; Glia-derived nexin; P17 antibody Peptidase inhibitor 7; Pi-7; Plasminogen activator inhibitor type 1, member 2; PN-1; PN1; PNI; Protease nexin 1; Protease nexin I; Serpin E2; Serpin peptidase inhibitor, clade E nexin, plasminogen activator inhibitor type 1, member 2; SERPINE 2; Serpine2. |
The serine protease inhibitors (serpins) compose a superfamily of proteins with a diverse set of functions, including the control of blood coagulation, complement activation, programmed cell death and development. Serpins are secreted glycoproteins that contain a stretch of peptide that mimics a true substrate for a corresponding serine protease. Protease nexin-1 (PN-1) is a serpin that inactivates several proteases, including thrombin, urokinase, plasminogen activators (PA) and plasmin. It is involved in tissue remodeling, cellular invasiveness, matrix degradation and tumor growth. PN-1 expression is abundant in the nervous system, where it inhibits thrombin, thereby playing a role in neural injury and repair processes. An imbalance between PN-1 and thrombin may be a contributing factor in the pathology of Alzheimer??s disease. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |